US Edition
Exclusive: Mikael Dolsten joins gene editing startup's board and eyes 'opportunities' with new FDA leaders
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Recently, during 2025, United States stock markets have been at a difficult stage, with the window of initial public presentations (IPO) for start-up companies shrinking, and the US Food and Drug Administration (FDA) suffering from unrest, and...
Exclusive: Mikael Dolsten joins gene editing startup's board and eyes 'opportunities' with new FDA leaders
Mikael Dolsten, Pfizer's former chief scientific officer who led the company’s Covid-19 vaccine development, has joined the board of Arbor Biotechnologies, a gene editing startup working on therapies for liver and neurological diseases, Arbor told ...
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
